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Abstract
Objective—To develop predictive models for early triage of burn patients based on hyper-
susceptibility to repeated infections.
Background—Infection remains a major cause of mortality and morbidity after severe trauma, 
demanding new strategies to combat infections. Models for infection prediction are lacking.
Methods—Secondary analysis of 459 burn patients (≥16 years old) with ≥20% total body surface 
area burns recruited from six US burn centers. We compared blood transcriptomes with a 180-h 
cut-off on the injury-to-transcriptome interval of 47 patients (≤1 infection episode) to those of 66 
hyper-susceptible patients (multiple [≥2] infection episodes [MIE]). We used LASSO regression 
to select biomarkers and multivariate logistic regression to built models, accuracy of which were 
assessed by area under receiver operating characteristic curve (AUROC) and cross-validation.
Results—Three predictive models were developed covariates of: (1) clinical characteristics; (2) 
expression profiles of 14 genomic probes; (3) combining (1) and (2). The genomic and clinical 
models were highly predictive of MIE status (AUROCGenomic = 0.946 [95% CI, 0.906–0.986]); 
AUROCClinical = 0.864 [CI, 0.794–0.933]; AUROCGenomic/AUROCClinical P = 0.044). Combined 
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model has an increased AUROCCombined of 0.967 (CI, 0.940–0.993) compared to the individual 
models (AUROCCombined/AUROCClinical P = 0.0069). Hyper-susceptible patients show early 
alterations in immune-related signaling pathways, epigenetic modulation and chromatin 
remodeling.
Conclusions—Early triage of burn patients more susceptible to infections can be made using 
clinical characteristics and/or genomic signatures. Genomic signature suggests new insights into 
the pathophysiology of hyper-susceptibility to infection may lead to novel potential therapeutic or 
prophylactic targets.
INTRODUCTION
Although several studies have found association between specific risk factors or clinical 
characteristics with mortality after trauma,1–4 studies attempting to apply those clinical 
characteristics or genomic biomarkers to appreciate susceptibility to infection and build 
predictive models are currently lacking. Improvements in early care and trauma centers have 
reduced early mortality considerably.3,5 However, severe trauma, such as burn trauma, cause 
immunosuppression which predispose patients to infections. Despite all medical 
improvements, infections remain a major cause of critical injury-related morbidity and 
mortality, and recurrent sepsis predisposes patients to multiple organ failure, lengthens 
hospital stays, and increases costs.6 Therefore, improvements in prevention and treatment of 
infections are increasingly important.7,8 Moreover, the rapid emergence of multi-(MDR) or 
pan-drug resistant (PDR) pathogens that cause highly problematic acute, persistent or 
relapsing infections pose a dire threat to healthcare, especially among trauma and surgical 
patients.9,10 The increased use of antibiotics has further accelerated their emergence,11–13 
and also increased the challenge of treating polymicrobial wound infections.14,15 Due to the 
paucity of novel anti-infectives in development, further improvement in patient care and 
treatment efficacy may rely heavily on optimizing existing strategies and promoting 
patients-tailored therapies.16–18
Successful personalized approach requires rigorous triaging: early and accurate 
identification of patients more susceptible to infections could help tailor the anti-infective 
treatments,19,20 and especially to elaborate long-term treatment plan. Future successful 
clinical trials aiming to improve sepsis outcome may also rely on biomarkers to identify the 
right patients for the right treatment.21,22 Several studies have reported risk factors 
associated with increased probability of infection and sepsis in trauma patients,23–26 but no 
specific predictive model has been developed. Existing plasma biomarkers such as C-
reactive protein (CRP) and procalcitonin (PCT) are mainly used to diagnose sepsis27,28 
rather than reflective of susceptibility or health status. The clinical characteristics 
measurable rapidly upon admission are the current gold standard for prognosis of general 
patient’s outcome.
As trauma promotes susceptibility to infection and genomic signatures appear to play an 
increasingly promising role in prognosis,26,29 we analyzed the blood transcriptome and 
clinical characteristics data of 113 patients from the 573 thermally injured patients enrolled 
in the Inflammation and the Host Response to Injury study. Using clinical characteristics 
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available upon admission and early genomic signatures, we developed novel predictive 
models that would permit early identification of burn patients at high risk of developing 
repeated infection indicative of an early hyper-susceptible state. The genomic signature 
suggests new mechanistic aspects for susceptibility to infection after burn trauma.
METHODS
Subject Recruitment and Sample Selection
This study was conducted via secondary use of the clinical and genomic data of the 
Inflammation and the Host Response to Injury Study (“Glue Grant”). Briefly, 573 burn 
patients with minimum 20% total burn surface area (TBSA) were enrolled from six 
institutions between 2003 and 2009 in a prospective, longitudinal study. RNA of leucocytes 
isolated from whole blood samples were extracted for transcriptome analysis using 
Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays at University of Florida–
Gainesville, as described previously.30 The complete inclusion/exclusion criteria are 
described elsewhere.31 Permission for this secondary use of the de-identified data was 
obtained from the Massachusetts General Hospital Institutional Review Board (MGH IRB 
protocol 2008-P-000629/1).
Our patient inclusion process is summarized in Figure 1. From 573 potential patients in the 
data pool, we selected for patients that were at least 16 years old with early transcriptome 
data. We set a 180-h cut-off limit on the injury-to-transcriptome interval to include only 
samples that were obtained early relative to the recovery process, while still allowing 
enough samples to remain eligible for biomarker discovery. If multiple blood samples were 
collected from a patient, only the earliest eligible sample was included. We excluded 
patients who died within 9 days of blood collection and had fewer than two infection 
episodes during this time window (Figure 1; Figure 1A). Our method for collection of data 
related to clinical characteristics is described elsewhere.31 To enable direct comparisons, as 
well as combination of clinical and genomic prediction, we used the same set of patients for 
both our clinical characteristic and our genomic signature prediction models.
Definition of Outcomes
We defined infections according to the information collected in the Glue Grant database 
based on previously described standards.32 Infection episodes were quantified for each 
patient for up to 60 days after blood sample collection. We developed a decision tree (Figure 
1B; Supplemental Digital Content[SDC] Table 1) for evaluating each record based on: (1) 
time of infection; (2) type of infection; and (3) the pathogen(s) isolated. Since no genotyping 
data of the isolated pathogen species were available, we were unable to classify whether a 
later episode was caused by the same strain isolated earlier. However, once a record was 
counted, the infection type and isolated pathogen combination (e.g. Pseudomonas 
aeruginosa + lung) was put on a “waiting list” for the next 6 days, which likely reduced the 
likelihood of an infection episode caused by the same isolate from being counted. 
Subsequent records that were part of the same infection episode were thereby omitted. The 
patients were separated into two groups based on susceptibility to infection, measured by the 
number of independent infection episodes recorded. We defined patients with ≤1 infection 
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episodes as the less susceptible control group (N = 47), and patients with ≥2 (multiple) 
infection episodes (MIE) as the hyper-susceptible case group (N = 66).
Microarray Processing and Filtering
Raw microarray data (.CEL files) were downloaded from the Glue Grant website (http://
www.gluegrant.org/trdb/) and filtered using the steps outlined in Figure 1, SDC Table 1 and 
Figure 1B. We used the gcrma33 package on the R/Bioconductor platform34 to normalize 
124 blood samples from 124 eligible patients collected within 180 h post-injury. Samples 
identified as outliers by arrayQualityMetrics35 were excluded from subsequent analysis. One 
patient was removed due to incompleteness of clinical data. Two patients’ datasets were 
discarded due to mortality within 9 days after sample collection. After these filtration steps, 
113 blood samples were deemed suitable high-quality microarray data sets for subsequent 
functional analyses, biomarker discovery, and modeling.
We used the EMA package36 in R software to filter outlying or information-poor probe sets. 
We eliminated probe sets with a maximum log2 expression value below 3.5, reducing the 
number of probe sets from 54,675 to 26,107. Using limma package,37 we selected 1142 
probe sets with an at least 1.5-fold difference between less susceptible patients and hyper-
susceptible patients and with an average expression level of at least 3 for functional analyses 
and biomarker panel selection process.
Statistical Analysis
Clinical data set—Continuous variables are reported as means (standard deviations), or as 
medians with inter-quartile ranges (IQRs) as indicated. Categorical variables are reported as 
frequencies and percentages. Demographic variables between less susceptible and hyper-
susceptible patients were tested for statistical difference with a Wilcoxon rank sums test, a 
Chi-square test, or a Fisher’s exact test as appropriate. Statistical significance was accepted 
at P < 0.05 (two-tailed when appropriate).
Body mass index (BMI) was calculated as weight/height2 (kg/m2). For patients ≥20 years 
old, BMI categories of underweight, healthy, overweight and obese were define according to 
BMI numbers: <18.5, 18.5–24.9, 25–29.9, and ≥30, respectively; whereas for patients <20 
years old, the same BMI categories were defined using percentile ranking based on Centers 
for Disease Control and Prevention BMI-for-age growth charts: <5th percentile, 5th to <85th 
percentile, 85th to <95th percentile, and ≥95th percentile, respectively.
Genomic data set—In our evaluation of significant expression differences between less 
susceptible and hyper-susceptible patients, Benjamini-Hochberg multiple-comparison 
adjustments were applied to control for false discovery rate.
Development of the clinical predictive models—We implemented stepwise logistic 
regression with an entry level of 0.3 and a stay level of 0.25 to identify significant predictor 
variables among clinical covariates relevant to the outcome variable of MIE: TBSA, age, 
BMI, and the presence of inhalation injury. We determined predictive power by calculating 
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area under receiver operating characteristic curve (AUROC), reported with 95% confidence 
intervals (CIs).
Development of the genomic predictive models—We used the LASSO regularized 
regression method38 implemented in the glmnet package39 in R software to identify probe 
sets that collectively predicted the likelihood of MIE. We used 10-fold cross-validation (CV) 
to select the optimal value of LASSO penalty weighting, λ. The value of λ that gave the 
minimum average binomial deviance plus 1 standard error on the test set, λ1se, was used to 
select probe sets (Figure 3A). λ1se is a stronger penalty parameter to guard against over-
fitting than λmin, which minimizes the average binomial deviance of CV (Figure 3B). This 
10-fold CV process was repeated 100 times to generate 100 λ1se values. The median λ1se, 
0.0940, yielded selection of a 14-probe-set biomarker panel (Figure 3C; Table 2). Logistic 
regression was performed to model the MIE outcome with the log2 expression values of the 
14 probe sets as explanatory variables. Furthermore, we conducted multivariate logistic 
regression with the clinical covariates TBSA, age, and inhalation injury together with the 14 
probe sets for the outcome variable of MIE. Leave-one-out cross-validation was used to 
assess the degree of over-fitting and model performance.
Functional Analysis
Functional and pathway analyses were conducted using Ingenuity IPA (Ingenuity® Systems, 
www.ingenuity.com) and DAVID.40
Software Platform and Package Versions
R (version 2.15.*); EMA package for R (version 1.3.2); pROC package for R (version 
1.5.4); limma package for R (version 3.14.4); glmnet package for R (version 1.9-3); 
arrayQualityMetrics package for R (version 3.14.0); gcrma package for R (version 2.30.0); 
JMP Pro 10 and SAS 9.3 (SAS Institute Inc., North Carolina, USA).
RESULTS
Clinical Characteristics
From a pool of 573 patients, 124 met our inclusion criteria, of which 11 were unsuitable for 
modeling, leaving a cohort of 113 patients (Figure 1), including 47 patients less susceptible 
to infection (control group with ≤1 infection episodes) and 66 hyper-susceptible patients 
(case group with multiple [≥2] infection episodes [MIE]). The demographics, injury 
characteristics, and outcomes of these 113 patients are summarized in Table 1.
From 612 microbiological records for the 113 patients in the final cohort, we identified 325 
independent infection episodes, 107 (32.9%) of which are polymicrobial at the species level. 
Twenty-four patients had no infection episodes, 23 had one episode, and 66 had MIE. The 
less susceptible and hyper-susceptible patients show significantly different clinical 
characteristics (Table 1). Relative to the control group, hyper-susceptible patients were 
slightly older (mean, 38.2, SD 16.4 vs 37.0, SD 14.6), had higher TBSA (46%, IQR 35–71 
vs 32%, IQR 23–41, P < 0.0001), had more inhalation injuries (41/66 [62.1%] vs 8/47 
[17.0%], P < 0.0001) and were more severely ill (according to their APACHE II score 24, 
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IQR 18–29 vs 13, IQR 9–20, P < 0.0001). They also had longer hospital stays (median, 60, 
IQR 33–71 vs 20, IQR 15–30, P < 0.0001), more days on mechanical ventilation (median, 
28, IQR13–40 vs 2, IQR 0–5, P < 0.0001), and had a higher mortality (18/66 [27.3%] vs 
3/47 [6.4%], P = 0.0029) (Table 1). The median post-injury interval for the second episode 
in the case group was 15 days (IQR, 10–20; range, 3–43), a time window that provides 
opportunity for prophylactic intervention.
Inhalation injury significantly increased the risk of developing MIE and may be related to 
pneumonia risk in particular: 78.8% of hyper-susceptible patients had pneumonia vs 10.6% 
of controls; among cases, 84.7% had both MIE and inhalation injuries, 67.4% had both 
pneumonia and inhalation injuries. Interestingly, 4/5 of underweight patients had MIE 
(Table 1), supporting the notion that being overweight and mild obesity may be protective 
against post-injury infection whereas being underweight increases risk.32,41
Burn wound infection and nosocomial pneumonia were the most frequent types of infection 
observed (Table 1; Figure 2A). Pseudomonas aeruginosa and Staphylococci (both 
Staphylococcus aureus and coagulase negative Staphylococci) were the most commonly 
isolated micro-organisms (Table 1; Figure 2B). P. aeruginosa and Acinetobacter infections 
were more common among patients with MIE than controls, suggesting that hyper-
susceptible patients were even more susceptible to nosocomial Gram-negative pathogens.
MIE Prediction from Clinical Characteristics
We used stepwise logistic regression to select covariates for modeling from TBSA, age, 
BMI, and the presence of inhalation injury. The final multivariate logistic regression model 
included three covariates: TBSA, age, and inhalation injury, which were significant 
independent predictors of MIE. The AUROC, CV AUROC, sensitivity, and specificity 
values for the clinical characteristics model are 0.845 (95% CI, 0.773–0.916), 0.838 (95% 
CI, 0.762–0.914), 0.803 (95% CI, 0.683–0.887), and 0.745 (95% CI, 0.594–0.856), 
respectively (Figure 3). The model’s positive and negative predictive values were 0.815 
(95% CI, 0.696–0.843) and 0.729 (95% CI, 0.579–0.843), respectively. Inhalation injury 
significantly increased MIE incidence (odds ratio [OR], 6.942; 95% CI, 2.482–19.417). 
Patients who had inhalation injuries were twice as likely to get pneumonia compared to 
those without them (risk ratio [RR], 2.05; 95% CI, 1.37–3.07). Among those who had 
inhalation injuries, 67.4% had pneumonia, and 83.67% had MIE. TBSA (OR, 1.078; 95% 
CI, 1.040–1.118) and age (OR, 1.040; 95% CI, 1.006–1.075) were also associated with 
increased infection susceptibility.
MIE Prediction from Genomic Biomarkers in Blood
Ten-fold CV using LASSO regularized regression38 of the 1142 probe sets that presented a 
minimum of 1.5-fold change between the two patient groups yielded a minimal set of 14 
predictors (probe sets) that together optimized the fit of the model (Figure 4A and 4B). Of 
these 14 probe sets—which mapped to 12 genes—4 were upregulated and 10 were down-
regulated (Table 2, all P < 0.01; see Figure 4C for heat map and clustering of patients and 
biomarkers; see Figure 2 for expression profiles of each probe set). The biological processes 
associated with each probe set are presented in Table 3 together with the coefficients of the 
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biomarker panel logistic regression model (model intercept = 0.7449; SDC Table 6). The 
AUROC, CV AUROC, sensitivity, and specificity values for the resulting genomic signature 
model are 0.946 (95% CI, 0.906–0.986), 0.872 (95% CI, 0.804 – 0.940), 0.924 (95% CI, 
0.825–0.972), and 0.830 (95% CI, 0.687–0.919), respectively (Figure 3), confirming the 
model to be highly sensitive and specific. The positive and negative predictive values of the 
model were 0.884 (95% CI, 0.779–0.945) and 0.886 (95% CI, 0.746–0.957), respectively. 
We compared each patient’s probability of developing MIE estimated from our clinical or 
genomic biomarker logistic regression models with each of the observed outcomes, using 
cut-off points of 30% to 70% as being uncertain. We found that the clinical model correctly 
predicted outcomes of 73 (65%) patients with certainty. Comparatively, the genomic 
biomarker model correctly predicted 90 (80%) patients with certainty, showing a 15% 
improvement over the clinical model. Both models misclassified 9 patients (8%). 
Collectively, these data suggest that genomic biomarkers may complement triage by clinical 
characteristics and enhance early prediction of a patient’s likelihood to develop MIE.
MIE Prediction from a Combined Model
A multivariate logistic model that included the aforementioned clinical covariates (TBSA, 
age, presence of inhalation injury) and genomic biomarkers resulted in an AUROC (0.967; 
95% CI, 0.940–0.993) that was significantly greater than that for the clinical model (P = 
0.0069), but not significantly different from that of the genomic biomarker panel model 
(Figure 3). The positive and negative predictive values of the combined model were 0.881 
(95% CI, 0.773–0.943) and 0.848 (95% CI, 0.705–0.932), respectively. The estimates of the 
above models are listed in SDC Table 6.
Functional and Canonical Pathway Changes in Patients with MIE Revealed by 
Transcriptome Data Analysis
The 1142 probe sets showing a minimum of 1.5-fold change in hyper-susceptible patients 
versus less susceptible patients were mapped to 844 annotated genes. We identified 
functionally related genes among these 884 genes using Gene Ontology (GO). Subsequent 
analysis of the changes in canonical pathways and functions linked to these 844 genes 
indicated that hyper-susceptible patients’ transcriptomes demonstrated the following early 
functional changes relative to control transcriptomes: (1) early activation of immune cells, 
increased chemotaxis and trafficking; (2) decreased expansion of leukocytes, thymocytes, 
and number of phagocytes, and increased cell death and apoptosis; and (3) suppression of 
immune cell activation and lymphoid organ development (Table 2). The 1142 probe sets 
showed enrichment in four main gene ontology biological process categories: (1) immune 
response; (2) epigenetic modulation of gene expression; (3) transcription; and (4) 
metabolism (SDC Tables 2). Functional enrichment clustering is also in agreement with the 
enrichment of the 4 functional groups (SDC Table 3). The top 30 affected pathways were 
mainly involved in immune cell signaling and cytokine signaling (Figure 5). Canonical 
pathway analysis using IPA software (Figure 5) largely agrees with KEGG pathway 
enrichment analysis using DAVID (SDC Table 5), providing additional confidence. Overall, 
many of the predicted functional changes (Table 2) are downstream of the affected canonical 
pathways (Figure 5; SDC Table 5).
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Canonical Pathways and T-cell Signaling—Significant changes in IL-8 signaling (17 
upregulated and 12 down-regulated genes [17 up/12 down]), Gαq signaling (16 up/9 down), 
Rho family GTPase signaling (20 up/10 down) and integrin signaling (21 up/9 down) 
suggest that the adhesion and migration of leukocytes are affected (Table 2; SDC Table 3; 
and Figure 5). The changes in chemotaxis may be partially caused by the presence of 
bacteria at wound site, as fMLP signaling pathway (12 up/8 down) suggests. Genes involved 
in phospholipase C signaling, a regulator of chemotactic response are differentially 
expressed (20 up/16 down). The increased cell movement, adhesion, and chemotaxis are 
related to phagocytosis process (e.g. FcγR-mediated phagocytosis, SDC Table 6), clearance 
of the pathogen from the site of infection, and induced by host damage associated molecular 
patterns (DAMP).
We found strong evidence that T-cells were also differentially regulated in case patients. 
Several pathways, including T-cell receptors (TCR) (7 up/16 down), JAK-STAT signaling 
(9 up/7 down), PKCθ signaling (8 up/15 down), and IL-6 signaling pathway (13 up/6 down) 
are known to regulate T-cell differentiation, activation, and cytokine production. Changes in 
iCOS-iCOSL signaling (10 up/14 down), CD28 signaling (11 up/16 down), and IL-2 
signaling (7 up/7 down), indicate that T helper cell maturation and proliferation were likely 
affected. In summary, patient transcriptome data is consistent with compromised cellular 
immune responses mediated by impaired T-cells signaling.
Functional Enrichment in Histone Modification and Chromatin Remodeling—
We found evidence for dramatic epigenetic changes in leukocytes that long precede patient 
outcome of MIE. Functions related to epigenetic modulation were commonly enriched in 
our functional enrichment analyses (SDC Tables 2, 3, and 4). Notably, 42 probe sets (39 
genes) have functional annotation associated with chromatin remodeling and histone 
modifications (SDC Table 4). Two genes from the biomarker panel involved in epigenetic 
modulation were found to be down-regulated in the case group with MIE: WHSC1L1, which 
encodes a histone lysine methyltransferase; and SMARCA4, which encodes an ATP-
dependent helicase related to the SWI/SNF chromatin remodeling factor. A multitude of 
differentially expressed genes encoding histone post-translational modifiers as well as key 
components of the nucleosome remodeling complex mediating ATP-dependent nucleosome 
sliding, including SMARCC1, SMARCA4, CHD2 and CHD9, were down-regulated (SDC 
Table 4). Other notable histone methyltransferases/demethylases differentially expressed 
include KDM4, KDM5C, KDM6, PRDM5, SETD2, SETDB2, and SUZ12. Genes coding for 
histone deacetylases/acetyltransferases and associated factors including HDAC9, KAT6A and 
EP400 were down-regulated and histone acetylation recognizing bromodomain containing 
protein, BRD2, was upregulated in the case group. Furthermore, critical non-histone 
heterochromatin proteins HP1-α and –γ were down-regulated, as well as core histone 
cluster. Taken together, our data may suggest a global loss of heterochromatin and genome 
instability, as well as probable gene-specific transcriptional deregulation in hyper-
susceptible patients compared to controls.
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DISCUSSION
The work presented reports novel predictive models for hyper-susceptibility to infection 
among traumatically injured patients, using genomic biomarkers and/or clinical 
characteristics that have not been used to build statistical prognostic models for the purpose 
of predicting infection outcomes. We provide evidence that our models can identify burn 
patients at high risk of developing repeated infections indicative of their hyper-susceptible 
state. To our knowledge, this work is the first to describe such models in trauma patients, 
and the first to describe functional transcriptome data of burn patients in relation to 
infections. The prediction accuracy of hyper-susceptibility to MIE is significantly increased 
over clinical markers when the genomic signature is used, providing strong evidence of the 
promising role of genomic biomarkers in prognosis even when used alone. By combining 
the biomarker panel with clinical characteristics, we demonstrated even better prediction 
accuracy, supporting the tremendous potential of using genomic signature to increase 
confidence in data used for treatment decision-making.
Clinical Implications
We identified two distinct patient groups with different genomic signatures and clinical 
characteristics, essentially allowing the rapid identification of patients with a high risk of 
developing MIE following burn trauma. Although burn patients generally suffer from 
immunosuppression, clinical experience and our data suggest that the severity of 
immunosuppression and infection outcome vary. These data suggest that patients could 
potentially receive personalized therapy depending on their susceptibility to infection, 
triaged by physical exam and a blood test on admission. This information could facilitate the 
determination of appropriate treatment courses, particularly in regards to antibiotic use, 
allowing for selective use of prophylactic antibiotics and more objective justification of 
length of treatment courses. For the patient, this could limit complications related to 
unneeded antibiotics, reduce the burden of lines needed to deliver the antibiotics, and 
streamline hospital care. For the population, this could promote antibiotic stewardship, help 
stem the emergence of resistant organisms, and reduce the cost of care.
Mechanistic Aspects
Genomic signatures provide insight into the molecular mechanisms of the more susceptible 
health status, and may aid in the discovery of novel therapeutic targets. Our findings point to 
novel potential targets for the prevention and/or early treatment of infections. Functional 
analyses of the 1142 biomarker candidates suggest new aspects into the pathophysiology of 
susceptibility to MIE after trauma. Susceptibility to MIE was associated with early 
alterations in numerous signaling pathways related to innate and adaptive immune 
responses, and changes in epigenetic modulation and metabolism.
Some of our findings are consistent with previous literature. For instance, upregulation of 
THBS1 (thrombospondin 1), to which 3/14 of the biomarker probe sets were mapped, has 
been associated with complicated recovery in blunt trauma patients,29 supporting the broad 
applicability of our approach and findings. The discovery of THBS1 also supports the 
potential biological relevance of our biomarkers. Indeed, increased expression of mouse 
Yan et al. Page 9
Ann Surg. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
homologue Thbs1 has been reported to be associated with infection,42 thrombosis, and 
increased lipopolysaccharide-induced mortality. Interestingly, Thbs1 −/− knockout mice 
show reduced susceptibility to peritoneal sepsis,43 whereas Thbs1 over-expressing 
transgenic mice show impaired wound healing associated with wound angiogenesis 
inhibition.44 THBS1 in human wounds could be functioning to provide adhesion target for 
pathogens through promotion of thrombosis,45 and/or delayed wound healing, which could 
lead to increased susceptibility to infection. Thus, building on convergent findings in 
humans and mice, our data confirm that processes related to coagulation play important 
roles in sepsis, and suggest that THBS1 could be a novel target for sepsis prevention and 
treatment.
We showed evidence for increased chemotaxis, cell adhesion, and migration of immune 
cells, and simultaneously, decreased expansion of immune cells and development of 
lymphatic system components. This seeming contradiction may well be the consequences of 
dysfunctional immune system and cytokine signaling, especially in T-cells.
Our data suggest that epigenetic changes occur early on, rather than mainly as a 
consequence of septic shock. Epigenetic regulation of immune system is a common 
mechanism for gene expression regulation and it plays a role in long-term 
immunosuppression after sepsis.46 Tightly regulated chromatin remodeling is required for 
transcriptional regulation, which is vital for proper host immune and inflammatory 
responses.47 Among the genes associated with epigenetic regulations, several have 
confirmed roles in immune responses, such as KAT6A and KDM6B (SDC Table 4).46,48–50 
Furthermore, our data further supports the notion that genes related to cell-cycle control and 
DNA repair have roles in both immune responses and tumorigenesis. In summary, the 
dramatic epigenetic changes could potentially explain why our biomarker panel could 
predict MIE that occurred weeks later, and the underlying mechanisms that favor infections 
by Gram-negative opportunistic pathogens.
Implications for Future Research
With the aforementioned clinical implications and mechanistic aspects, our findings lay the 
groundwork for a new pathway of investigation potentially applicable to other forms of 
trauma and possibly even useful in determining patient risk for MIE prior to elective 
surgical procedures. This study provides a much-needed new direction for future clinical 
trials. In particular, appropriate biomarkers and additional information regarding patient 
health status might be essential for successful clinical trials of anti-sepsis drugs.21,22 
Identification of the hyper-susceptible patients could enable more focused study design 
when expensive/invasive interventions, such as for the testing of cutting-edge technologies 
or products are involved by directing intervention to those who need it most. Identification 
of this group early after admission could also allow adjunctive treatments such as 
immunotherapy, extra-corporeal lipopolysaccharide removal, and other novel treatments to 
be tested prior to the decline of the patient’s clinical status due to MIE.
We envision that the development of a comprehensive diagnostic tool set will depend on the 
integration of genomic signatures of both host and pathogen. The blood biomarkers reported 
could be further developed and integrated with other diagnostic tools, such as genomic 
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single nucleotide polymorphisms (SNPs) that predispose certain patients to infection,51,52 
and produce a more comprehensive prognosis of patient susceptibility. Physician decisions 
rely heavily on blood tests over the course of recovery, and a positive culture is still the most 
accepted and reliable method for diagnosing infection. Using biomarkers, these blood 
samples could also allow us to monitor the changes in susceptibility status and adjust 
treatments accordingly. Modern molecular based microbiological tests,53 such as detection 
of P. aeruginosa in wound biopsy using RT-PCR based assays,54 have been developed but 
not yet widely utilized. Several molecular early detection kits have become commercially 
available for diagnosing common bloodstream infections, and have been found to show 
some promise despite of much room left for improvement.55,56 Our biomarkers on the host 
response may work synergistically with these tests to support physician decisions.
The discovery of these biomarkers and the validation of the methods pave the way for 
identifying biomarkers from other tissues involved in host defense, such as muscle, fat, and 
skin samples,57 of which often become available from surgical procedures or wound 
debridement. Biomarkers from other tissues may further enhance a combined model or 
perhaps provide even better prognostic value than blood biomarkers and clinical 
characteristics.
This study is limited by the unavailability of pathogen genotyping information below 
species level. We could not distinguish whether a reoccurring infection was caused by 
persistent or MDR pathogen, and could not identify biomarkers that can potentially 
differentiate susceptibility to different pathogens, such as Gram positive/negative bacteria, 
and even to species level. Nonetheless, our 6-day window (SDC Figure 1B) was designed to 
minimize infection episodes caused by the same strain(s). Our definition of hyper-
susceptibility is based on natural definition of having repeated infections. Changing this 
definition, for example, to having at least three infection episodes, did not significantly 
change the biomarkers identified (data not shown). However, the P values for differential 
gene expression and clinical characteristics became less significant, suggesting either the 
criterion is not the best cut off point to separate two different groups, or that the statistical 
power is reduced due to smaller number of patients in the hyper-susceptible group.
Although this work and our model focused on thermally injured trauma patients, our 
approach is potentially applicable to other types of trauma and surgical patients. In this 
study, to ensure portability of our models, we carried out rigorous internal CV to ensure 
robustness of our regression models. However, due to the novelty of this clinical and 
transcriptome dataset, independent cohort data was unavailable for CV. Although our 
dataset is the largest of its kind to date, the sample size is still too small to build a larger 
panel without risking over-fitting the model. Our genomics data warrant future trials with a 
larger randomized cohort study, as well as mechanistic interrogations using animal models. 
Our findings open new avenues for the prevention and treatment of repeated infections in 
critical care, and provide novel components for the development of integrated prognosis and 
diagnosis using biomarkers, SNPs and pathogen detection. Future studies should investigate 
the potential broad applicability, and assess whether early triage based on predictive models 
can improve outcomes of trauma patients.
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Figure 1. Sample selection process
aDevelopment of predictive models and discovery of biomarkers.
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Figure 2. Type of infections and isolated pathogens
A. Types of infection. One case of pseudomembranous colitis represents 0.2%. B. The 
percentage of isolated pathogens among all infection records.
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Figure 3. Clinical and genomic prediction models
ROC curves of the clinical model, genomic model, and combined model, and their 
respective AUROC, cross-validated (CV) AUROC, sensitivities, and specificities; 95% CIs 
are reported in parentheses. The blue, orange, and black lines are the ROC curves for the 
biomarker panel model, clinical model, and combined model, respectively.
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Figure 4. Biomarker selection by LASSO regularized regression
A. A representative repetition of 10-fold CV LASSO that chose 14 probe sets at λ1se. The 
first vertical dotted line corresponds to the λmin that minimized binomial deviance during 
CV. The second dotted line corresponds to λ1se, used for the selection of 14 probe sets as 
shown in B. B. LASSO coefficient profile plot of the coefficient paths. At λ1se, as shown 
with the dotted line, 14 probe sets have their coefficients significantly different from zero 
and thus were chosen as part of the biomarker panel. C. Heat map showing the expression 
levels of the 14 probe sets selected by LASSO as covariates for the genomic model. Each 
column corresponds to one of the 113 patient samples. Each row corresponds to one of the 
14 probe sets. Whenever available, gene names were provided (see Table 2 for Affymetrix 
probe identification). The heat map color-coding is based on probe-set-specific, re-
normalized expression values, with red signifying upregulation, blue signifying down-
regulation, and white indicating no difference in the hyper-susceptible patients compared to 
the controls. Patients that developed MIE are labeled red and those that had <2 infection 
episodes are labeled green at the bottom of the heat map.
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Figure 5. Pathways significantly altered
Top 30 pathways significantly altered in case group with MIE. X-axis is the negative log P 
value calculated from Fisher's exact test right-tailed. Red/Green inside bars are the number 
of upregulated/down-regulated genes. The total number of genes in a pathway is indicated in 
the parenthesis after pathway name. P value is calculated by Fisher’s exact test by IPA 
software.
Yan et al. Page 19
Ann Surg. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yan et al. Page 20
Table 1
Demographics and clinical characteristics of participants.
All (n=113)
Controls (≤1
Infectious
Episodes)
(n=47)
Cases (≥2
Infectious
Episodes
[MIE])
(n=66) P value
Age when injured, mean (SD), y 37.7 (15.6) 37.0 (14.6) 38.2 (16.4) 0.681
Sex, n (%) males 90 (79.6%) 40 (85.1%) 50 (75.8%) 0.218
BMI Category, n (%) 0.888
  Underweight 5 (4.4%) 1 (2.1%) 4 (6.1%)
  Healthy 44 (38.9%) 19 (40.4%) 25 (37.9%)
  Overweight 35 (31.0%) 15 (31.9%) 20 (30.3%)
  Obese 29 (25.7%) 12 (25.6%) 17 (25.8%)
Severity of Injury
  APACHE II Score, median (IQR) 20 (12–26) 13 (8–20) 24 (18–28) <0.001*
  Burns size of TBSA, % (IQR) 40 (28–56) 32 (23–40) 46 (35–70) <0.001*
  Presence of Inhalation Injury, n (%) 49 (43.4%) 8 (17.0%) 41 (62.1%) <0.001*
Outcome
  Hospital Stay, d (IQR) 35 (19–62) 20 (15–27) 60 (33–71) <0.001*
  Hospital Stay of Survived, d (IQR) 36 (19–62) 20.5 (15–27) 61 (44–72) <0.001*
  Days on Ventilation, d (IQR) 13 (2–33) 2 (0–5) 28 (13–40) <0.001*
  Day of Death Since Injury, d (IQR) 34 (18–63) 21 (18–21) 35.5 (18–65) 0.3753
  Mortality, no. (%) 21 (18.6%) 3 (6.38%) 18 (27.3%) 0.0029*
Number of Records by Type of Infection, n (%)
  Burn wound 332 (54.2%) 24 (60%) 308 (53.8%)
  Pneumonia 151 (24.7%) 8 (20%) 143 (25.0%)
  Bloodstream 59 (9.6%) 1 (2.5%) 58 (10.1%)
  Urinary tract 45 (7.4%) 7 (17.5%) 38 (6.6%)
  Catheter-related bloodstream 24 (3.9%) 0 (0%) 24 (4.2%)
  Pseudomembranous colitis 1 (0.2%) 0 (0%) 1 (0.2%)
Number of Records by Isolated Pathogens, n (%)
  P. aeruginosa 92 (15.0%) 4 (10%) 88 (15.4%)
  S. aureus 81 (13.2%) 7 (17.5%) 74 (13.0%)
  Coagulase negative Staphylococci 77 (12.6%) 6 (15.0%) 71 (12.4%)
  Enterococcus 47 (7.7%) 4 (10.0%) 43 (7.5%)
  Acinetobacter 45 (7.4%) 1 (2.5%) 44 (7.7%)
  Candida species 43 (7.0%) 0 (0%) 43 (7.5%)
  E. coli 34 (5.6%) 1 (2.5%) 33 (5.8%)
  Enterobacter species 28 (4.6%) 1 (2.5%) 27 (4.7%)
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All (n=113)
Controls (≤1
Infectious
Episodes)
(n=47)
Cases (≥2
Infectious
Episodes
[MIE])
(n=66) P value
  Gram negative NOS 27 (4.4%) 0 (0%) 27 (4.7%)
  K. pneumoniae 22 (3.6%) 0 (0%) 22 (3.8%)
  Others 116 (18.9%) 16 (40%) 100 (17.5%)
*
P < 0.05.
Abbreviations: BMI, body mass index; IQR, inter-quartile range; TBSA, total body surface area.
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Table 3
Predicted early functional changes in case group that had MIE.
Functions annotation P value
Activation z-
score # of genes
Increased
Chemotaxis <0.001 3.924 55
Chemotaxis of cells <0.001 3.924 54
Homing of cells <0.001 3.815 59
Chemotaxis of leukocytes <0.001 3.795 37
Chemotaxis of phagocytes <0.001 3.546 30
Chemotaxis of myeloid cells <0.001 3.501 29
Homing of leukocytes <0.001 3.484 41
Replication of Influenza A virus <0.001 3.413 38
Replication of virus <0.001 3.314 64
Leukocyte migration <0.001 3.088 100
Inflammatory response <0.001 3.085 72
Viral infection <0.001 3.046 166
Cytostasis <0.001 2.913 30
Replication of RNA virus <0.001 2.782 56
Cell movement <0.001 2.766 173
Migration of cells <0.001 2.619 161
Tyrosine phosphorylation of protein <0.001 2.456 29
Recruitment of cells <0.001 2.451 34
Recruitment of granulocytes <0.001 2.405 26
Polarization of leukocytes <0.001 2.337 13
Recruitment of leukocytes <0.001 2.333 33
Adhesion of immune cells <0.001 2.271 40
Recruitment of myeloid cells <0.001 2.263 27
Adhesion of blood cells <0.001 2.250 41
Cell viability <0.001 2.240 112
Orientation of macrophages <0.001 2.200 6
Attachment of cells <0.001 2.166 18
Disassembly of focal adhesions <0.001 2.164 7
Formation of membrane ruffles <0.001 2.137 12
Cell survival <0.001 2.101 121
Cell movement of neutrophils <0.001 2.067 37
Invasion of breast cancer cell lines <0.001 2.064 25
Orientation of cells <0.001 2.028 19
Decreased <0.001
Development of lymphoid organ <0.001 −3.241 30
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Functions annotation P value
Activation z-
score # of genes
Development of lymphatic system component <0.001 −2.970 41
Bacterial infection <0.001 −2.890 47
Expansion of leukocytes <0.001 −2.753 25
Expansion of lymphocytes <0.001 −2.635 21
Development of lymph node <0.001 −2.608 14
Morphology of germinal center <0.001 −2.415 11
Morphology of lymph follicle <0.001 −2.415 15
Expansion of blood cells <0.001 −2.384 26
Encephalitis <0.001 −2.374 27
Inflammation of organ <0.001 −2.362 97
Quantity of neutrophils 0.0011 −2.208 23
Development of thymocytes <0.001 −2.189 13
Quantity of granulocytes <0.001 −2.133 36
Organismal death <0.001 −2.074 196
An absolute z-score of ≥2 was designated as significant by the IPA software. The numbers of genes used to predict functional changes are indicated 
in the column with the heading “# of genes”.
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